Blog
EQS-News: Linde Announces First Quarter 2023 Earnings and Conference Call Schedule
EQS-News: Linde Announces First Quarter 2023 Earnings and Conference Call Schedule
EQS-News: Deutsche Postbank Funding Trust I: Preliminary announcement on the publication of financial reports pursuant to Sections 114, 115, 117 WpHG
EQS-News: Deutsche Postbank Funding Trust I: Preliminary announcement on the publication of financial reports pursuant to Sections 114, 115, 117 WpHG
Interroll - new Managing Director for Singapore
Interroll - new Managing Director for Singapore
EQS-News: CPI PROPERTY GROUP – Tender Offer Results
EQS-News: CPI PROPERTY GROUP – Tender Offer Results
Cairn Homes Plc: Transaction in Own Shares
Cairn Homes Plc: Transaction in Own Shares
Samarkand Group plc : Trading Update
Samarkand Group plc : Trading Update
Director Declaration
Director Declaration
Unaudited NAV for March 2023
Unaudited NAV for March 2023
AGM Update - the I-RES Board unanimously recommends shareholders vote FOR all proposed resolutions at the 2023 AGM
AGM Update - the I-RES Board unanimously recommends shareholders vote FOR all proposed resolutions at the 2023 AGM
EQS-News: Defence Therapeutics Inc.: DEFENCE'S NOVEL ACCUMTM-mRNA VACCINE NOW ADMINISTERED FOR TESTING ON CANCER
EQS-News: Defence Therapeutics Inc.: DEFENCE'S NOVEL ACCUMTM-mRNA VACCINE NOW ADMINISTERED FOR TESTING ON CANCER
Cicor achieves sales growth of 24.8% in the first quarter of 2023
Cicor achieves sales growth of 24.8% in the first quarter of 2023
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Sales for the first quarter 2023 Ad hoc announcement pursuant to Art. 53 LR
Sales for the first quarter 2023
Ad hoc announcement pursuant to Art. 53 LR
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-Adhoc: TRATON SE announces preliminary 3M 2023 results
EQS-Adhoc: TRATON SE announces preliminary 3M 2023 results
Cairn Homes Plc: Holding(s) in Company
Cairn Homes Plc: Holding(s) in Company
GEVELOT S.A.: PRESS RELEASE CLOSING OF 2022 ACCOUNTS
GEVELOT S.A.: PRESS RELEASE CLOSING OF 2022 ACCOUNTS
Rights and Issues Investment Trust PLC: POS-Transaction in Own Shares
Rights and Issues Investment Trust PLC: POS-Transaction in Own Shares
NORNICKEL DISCONTINUES DISCLOSURE VIA PRIMARY INFORMATION PROVIDER
NORNICKEL DISCONTINUES DISCLOSURE VIA PRIMARY INFORMATION PROVIDER
EQS-News: Nagarro releases audited financial results for 2022, announces share buyback
EQS-News: Nagarro releases audited financial results for 2022, announces share buyback
EQS-Adhoc: Management Board of Nagarro SE resolves on share buyback program with a volume of up to 30 million euros
EQS-Adhoc: Management Board of Nagarro SE resolves on share buyback program with a volume of up to 30 million euros
Rights and Issues Investment Trust PLC: NAV-Net Asset Value(s)
Rights and Issues Investment Trust PLC: NAV-Net Asset Value(s)
Hardman & Co Q&A on City of London Investment Group (CLIG): Continuing its good performance
Hardman & Co Q&A on City of London Investment Group (CLIG): Continuing its good performance
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: IBU-tec advanced materials AG: Ulrich Weitz will not move to the Supervisory Board in 2023
EQS-News: IBU-tec advanced materials AG: Ulrich Weitz will not move to the Supervisory Board in 2023


